Article Text

PDF

A double-blind controlled trial of the effect of sodium cromoglycate in preventing relapse in ulcerative colitis.
  1. P. J. Whorwell,
  2. G. M. Whorwell,
  3. J. Bamforth,
  4. D. Colin Jones,
  5. P. Down,
  6. A. Edwards,
  7. A. E. Gent,
  8. P. Golding,
  9. K. R. Gough,
  10. M. D. Hellier,
  11. P. Isaacson,
  12. C. A. Loehry,
  13. G. J. Milton-Thompson,
  14. C. L. Smith,
  15. R. P. Waldram,
  16. R. Wright

    Abstract

    A double-blind controlled trial of the effect of sodium cromoglycate (SCG) in preventing relapse in ulcerative colitis has been completed in 100 subjects. In patients already taking sulphasalazine, SCG did not prove to be of any additional benefit. However, in patients not on any other maintenance therapy, the relapse rate was 40% for SCG as compared with 75% for placebo. A large study of the effect of SCG in patients intolerant of sulphasalazine is indicated.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.